Profile: Medicines Co (MDCO.O)
The Medicines Company, incorporated on July 31, 1996, is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). The Company's pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. The Company sells over three of its acute care generic products, including midazolam, ondansetron and rocuronium.
Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. The Company licensed Angiomax from Biogen Idec, Inc. Angiomax is used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing Percutaneous transluminal coronary angioplasty (PTCA) and for patients undergoing Percutaneous Coronary Intervention (PCI), with provisional use of glycoprotein IIb/IIIa receptor inhibitors, or GP IIb/IIIa inhibitors, including patients with or at risk of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis syndrome (HIT/HITTS). Angiomax is used as an anticoagulant in adult patients undergoing PCI, including patients with ST Segment Elevation Myocardial Infarction (STEMI) undergoing primary PCI. Angiomax is also used as a treatment of adult patients with unstable angina or non-STEMI planned for urgent or early intervention, when used with aspirin and clopidogrel.
Cleviprex is an intravenous small molecule calcium channel blocker. The Company licensed Cleviprex from AstraZeneca AB. The Company's Cleviprex is used for the reduction of blood pressure when oral therapy is not feasible or not desirable. The new formulation of Cleviprex is used for various indications, including for short term treatment of hypertension when oral therapy is not feasible or desirable in Australia, for management of acute elevation of blood pressure in perioperative settings in Canada, and for the rapid reduction of blood pressure in perioperative settings in the European Union and Switzerland. The original formulation of Cleviprex is indicated for the reduction of blood pressure when rapid and predictable control is desired.
The Company's IONSYS (fentanyl iontophoretic transdermal system) is a compact, needlefeee patient-controlled system for the short-term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. Ionsys provides on-demand analgesia, which avoids the analgesic gaps, and eliminates the programming and other issues associated with intravenous patient controlled analgesia (IV PCA) pump.
The Company's Kengreal is an intravenous small molecule antiplatelet agent approved as an adjunct to PCI, for reducing the risk of periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. In patients undergoing PCI, the use of antiplatelet agents to block platelet activation through the platelet P2Y12 receptor and reduce the risk of clot formation is considered important therapy based on several studies of oral platelet inhibitors that have demonstrated patient outcomes in coronary angioplasty.
The Company's Minocin IV is an intravenous formulation of a tetracycline-class antibiotic that is used for the treatment of infections due to susceptible strains of designated gram-negative bacteria, including those due to Acinetobacter spp, Escherichia coli, Enterobacter aerogenes, Shigella species, respiratory tract infections caused by Haemophilus influenza and respiratory tract and urinary tract infections caused by Klebsiella species. Minocin IV is also indicated for the treatment of infections caused by the microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug, including skin and skin structure infections caused by Staphylococcus aureus and upper respiratory tract infections caused by Streptococcus pneumoniae.
The Company's Orbactiv is an intravenous antibiotic that is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA), with a single dose treatment. Orbactiv is synthetically modified from a naturally occurring compound.
ABP-700 is an intravenous anesthetic agent being developed for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures. ABP-700 is a positive allosteric modulator of the a-aminobutyric acid type A (GABAA) ligand-gated ion channel. The endogenous ligand for this channel is GABA, the inhibitory neurotransmitter in the central nervous system. ABP-700 has an ester bond that undergoes rapid cleavage through non-specific tissue esterases producing an inactive carboxylic acid metabolite. ABP-700 is under clinical development in the Phase I trials.
ALN-PCSsc is a subcutaneously administered PCSK9 synthesis inhibitor, which works through RNA interference (RNAi), and is being developed for the potential treatment of hypercholesterolemia. The Company is engaged in developing, manufacturing and commercializing RNAi therapeutics targeting the PCSK9 gene for the treatment of hypercholesterolemia and other human diseases. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. PCSK9 is a gene involved in the regulation of low-density lipoprotein (LDL), receptor levels on hepatocytes and the metabolism of LDL cholesterol, or LDL-C, which is referred to as bad cholesterol. ALN-PCSsc is designed to inhibit the synthesis of PCSK9 and lead to reduced levels of LDL-C.
Carbavance is an antibiotic agent, which is under development for the treatment of hospitalized patients with serious gram-negative bacterial infections, including complicated urinary tract infections, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia, and bacteremia. Carbavance is a combination of vaborbactam, a beta-lactamase inhibitor, with meropenem. Carbavance is focused on addressing carbapenem-resistant Enterobacteriaceae (CRE). The Company is engaged in developing Carbavance for the treatment of serious gram-negative infections in hospitalized patients, particularly in the setting of documented or suspected infections due to Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae in patients.
The Company's MDCO-216 is a biologic and complex of a phospholipid and recombinantly manufactured ApoA-1 Milano, a naturally occurring variant of ApoA-1, a protein found in human high-density lipoprotein, or HDL. MDCO-216 has the ability to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS by stimulating the ABCA1 dependent cholesterol efflux pathway, which is the first step in reverse cholesterol transport.
The Company competes with Eli Lilly, Johnson & Johnson/Centocor, Inc., Merck & Co., Inc., Iroko Pharmaceuticals, LLC, MediCure Inc., GlaxoSmithKline, West-Ward Pharmaceuticals, Sandoz, Teflaro, Cubicin, Zyvox, Vibativ, Durata Therapeutics, Inc., Bristol Meyers Squibb, Sanofi, Daiichi Sankyo, AstraZeneca, and AcelRx, Inc.
8 SYLVAN WAY
PARSIPPANY NJ 07054
Company Web Links
- Medicines Co drug shows long-term cholesterol lowering in study
- Medicines Co drug shows long-term cholesterol lowering in study
- BRIEF-Medicines Co reports Q4 loss per share $1.77 from continuing operations
- BRIEF-Medicines Co says FDA accepts NDA filing for intravenous antibiotic carbavance
- BRIEF-Mylan signs sub-license agreement with the Medicines Patent Pool to produce and market DAKLINZA tablets to 112 countries